Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
sabato, ottobre 03
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Takeda Pharmaceutical Co Ltd
TAK
NYSE
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$17.86
N/A
Ult. Agg.: Oct 2, 4:00 PM
$17.86
N/A
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Dati finanziari
Sentiment
Azionariato
Dividendi
Confronta
Opzioni
Rapporto azionario
Privacy Manager
Dividendo:
La data di stacco del dividendo è tra 10 giorni
Takeda Pharmaceutical Co Financials
Takeda Pharmaceutical Co (TAK) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
CORRECTION: Takeda Pharmaceutical Co Affirms FY2026 Adj EPS Guidance of $3.01 vs $1.57 Est; Affirms FY2026 Sales Guidance of $29.585B vs $28.950B Est
Takeda Pharmaceutical Co (NYSE:TAK) affirms FY2026 Adj EPS guidance from $3.01 to $3.01 vs $1.57 analyst estimate. Affirms FY2026 sales outlook from $29.585 billion to $29.585 billion vs $28.950 billion estimate.
Benzinga Newsdesk
PRO
Takeda Pharmaceutical Co Affirms FY2026 GAAP EPS Guidance of $0.66; Affirms FY2026 GAAP Sales Guidance of $29.585B
Takeda Pharmaceutical Co (NYSE:TAK) affirms FY2026 GAAP EPS guidance from $0.66 to $0.66. Affirms FY2026 sales outlook from $29.585 billion to $29.585 billion.
Benzinga Newsdesk
PRO
Takeda Pharmaceutical Q1 Adj. EPS $0.48 Beats $0.39 Estimate, Sales $7.655B Beat $7.060B Estimate
Takeda Pharmaceutical (NYSE:TAK) reported quarterly earnings of $0.48 per share which beat the analyst consensus estimate of $0.39 by 23.08 percent. This is a 7.69 percent decrease over earnings of $0.52 per share from
Benzinga Newsdesk
Takeda's Next Wave Of Drugs Has Investors Watching Closely
Takeda eyes growth with FDA Priority Reviews for narcolepsy and PV drugs. Get the latest on TAK's late-stage pipeline and 2026 forecasts.
Vandana Singh
Earnings Scheduled For May 13, 2026
Benzinga Insights
PRO
Takeda Pharmaceutical Co Sees FY2026 GAAP EPS $0.66.
Takeda Pharmaceutical Co (NYSE:TAK) is looking for FY2026 GAAP EPS of $0.66.
Benzinga Newsdesk
